Table 3.
Clinical parameters of patients treated with daily DPP4 inhibitors or weekly omarigliptin
| Month of study | Control (n = 28) | Omarigliptin (n = 56) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 3 | 6 | 9 | 12 | 0 | 3 | 6 | 9 | 12 | |
| FBG (mg/dl) | 130.8 (24.8) | 129.5 (22.9) | 129.8 (28.8) | 127.8 (30.6) | 129.0 (26.8) | 133.8 (19.1) | 129.6 (24.6)* | 123.7 (29.3)* | 123.6 (18.1)* | 117.1 (18.7)* |
| IRI (μU/ml) | 7.12 (1.87) | 7.15 (3.02) | 7.26 (3.05) | 7.21(2.49) | 7.31 (3.32) | 7.37 (3.7) | 6.40 (3.14)* | 5.56 (2.71)* | 5.21(2.3)* | 4.72 (2.12)* |
| HOMA-IR | 2.60 (1.29) | 2.58 (1.28) | 2.54 (1.34) | 2.51 (1.57) | 2.43 (1.81) | 2.56 (1.44) | 2.16 (1.49)* | 1.73 (0.95)* | 1.62 (0.89)* | 1.45 (0.77)* |
| HbA1c (%) | 6.85 (0.75) | 6.79 (0.84) | 6.79 (0.75) | 6.75 (0.93) | 6.81(0.79) | 6.91 (0.77) | 6.86 (0.73) | 6.86 (0.87) | 6.79 (0.81)* | 6.73 (0.72)* |
| BMI | 25.4 (3.2) | 25.7 (4.3) | 25.6 (3.3) | 25.5 (3.1) | 25.5 (3.7) | 24.9 (3.2) | 24.7 (3.2) | 24.3 (4.7) | 24.6 (3.1) | 24.6 (3.1) |
| log (hsCRP) | − 0.98 (0.44) | − 0.98 (0.43) | − 0.87 (0.54) | − 0.89 (0.36) | − 0.87 (0.29) | − 0.96 (0.30) | − 1.14 (0.31)* | − 1.23 (0.32)* | − 1.31 (0.33)* | − 1.39 (0.33)* |
| LDL-C (mg/dl) | 103.6 (24.1) | 101.2 (23.9) | 101.1 (25.8) | 101.9 (24.5) | 103.8 (27.2) | 102.8 (23.6) | 102.0 (24.7) | 102.5 (23.6) | 98.6 (26.8) | 95.7 (25.9)* |
| HDL-C (mg/dl) | 57.1 (12.9) | 56.5 (11.8) | 56.7 (13.7) | 57.5 (12.1) | 55.4 (12.3) | 57.3 (12.8) | 57.8 (14.9) | 57.3 (12.8) | 57.8 (12.6) | 56.2 (16.2) |
| TG (mg/dl) | 129.4 (61.3) | 139.8 (81.7) | 142.6 (64.1) | 139.9 (58.4) | 153.5 (75.0) | 124.1(68.5) | 121.6 (53.3) | 114.3 (50.0) | 106.0 (45.5)* | 103.1 (33.7)* |
| RLP-C (mg/dl) | 4.77 (3.66) | 4.74 (3.65) | 4.72 (3.28) | 4.61 (3.13) | 4.51 (2.57) | 4.78 (3.19) | 4.34 (2.15)* | 3.73 (1.78)* | 3.36 (1.49)* | 2.91 (0.94)* |
| AST (IU/L) | 25.6 (14.6) | 25.2 (8.1) | 25.4 (7.7) | 25.1 (5.9) | 25.7 (6.9) | 24.4 (10.5) | 22.6 (7.1)* | 22.7 (7.8) | 22.8 (8.4) | 22.3 (6.6) |
| ALT (IU/L) | 25.2 (12.6) | 25.3 (14.6) | 24.4 (16.2) | 24.3 (17.3) | 25.7 (14.6) | 25.0 (15.5) | 23.1 (11.7) | 23.6 (12.2) | 23.1 (10.8) | 21.6 (10.9)* |
| γGTP (IU/L) | 40.1 (35.6) | 39.5 (32.4) | 40.7 (33.6) | 38.5 (29.7) | 38.3 (30.8) | 38.8 (33.7) | 38.6 (34.0) | 35.7 (25.4) | 33.8 (33.7) | 31.5 (19.8)* |
| eGFR (mL/min/1.73m2) | 69.4 (16.7) | 68.5 (18.8) | 69.6 (18.2) | 69.7 (15.6) | 69.7 (17.5) | 68.0 (13.1) | 68.2 (13.3) | 68.2 (14.5) | 67.9 (14.1) | 67.8 (13.4)* |
| log (ACR) | 1.18 (0.59) | 1.20 (0.51) | 1.23 (0.56) | 1.27 (0.59) | 1.27 (0.44) | 1.27 (0.56) | 1.13 (0.58)* | 1.18 (0.56) | 1.17 (0.56) | 1.12 (0.60)* |
| SBP (mmHg) | 125.0 (15.8) | 127.0 (18.4) | 126.6 (17.5) | 125.1 (18.5) | 124.7 (16.6) | 123.7 (14.3) | 119.5 (13.0)* | 121.4 (12.3) | 119.8 (12.3)* | 118.4 (12.9)* |
| DBP (mmHg) | 70.5 (10.3) | 70.8 (9.3) | 70.1 (9.7) | 70.2 (10.7) | 70.5 (14.2) | 70.5 (9.0) | 68.4 (9.8) | 69.6 (8.7) | 68.2 (8.3) | 67.9 (9.0)* |
Values are shown as mean ± SD in parentheses
FBG, fasting blood glucose; IRI, immunoreactive insulin; HOMA-IR, homeostatic model assessment of insulin resistance; HbA1c, hemoglobin, A1c; BMI, body mass index; hsCRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density, lipoprotein cholesterol; TG, triglyceride; RLP-C, remnant-like particle cholesterol; AST, aspartate aminotransferase; ALT, alanine, aminotransferase; γGTP, gamma-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure
* Intragroup comparison: p < 0.05 (paired t test)